secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013608
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances
--------------------------------------------------------------------------------

- Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
- Full-year net loss $17.1M ($1.57/share) vs $20.8M ($1.93/share) in 2024; R&D expenses down 29% to $11.5M.
- LP-300 HARMONIC trial: FDA Type C meeting scheduled mid-May 2026 to discuss protocol amendments focusing on EGFR exon 21 L858R patients.
- LP-184 Phase 1a complete: 48% clinical benefit rate; Phase 1b/2 trials planned in TNBC, NSCLC with STK11/KEAP1 mutations.
- withZeta.ai beta testing with 25+ biotech firms; company denies false report of CEO resignation, confirms Panna Sharma remains CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer